Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thymoma 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Lung Neoplasms 1Liver Neoplasms 1Colonic Neoplasms 1Choriocarcinoma 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Cyclophosphamide 7pembrolizumab 6Radiotherapy 6Cisplatin 6Sunitinib 5Carboplatin 5Paclitaxel 4Thymectomy 3130-nm albumin-bound paclitaxel 3selinexor 2lenvatinib 2fludarabine 2Taxes 2Robotic Surgical Procedures 2Ramucirumab 2Prednisone 2Pemetrexed 2Octreotide 2Nivolumab 2N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 2Methylprednisolone 2Imatinib Mesylate 2Etoposide 2Erlotinib Hydrochloride 2Drug Therapy 2Doxorubicin 2Chemoradiotherapy 2Celecoxib 2zimberelimab 1vorolanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thymoma × saracatinib × Thoracic × Clear all
NCT00718809 2015-06-10

Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
21 enrolled 13 charts
Thoracic

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡